Lucentis (ranibizumab) faces oncoming competition from 4 companies that are developing proposed biosimilars.
New Year, New Hurdles: What's in Store for Biosimilars in 2023
December 18th 2022On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
Sandoz' Dr Sonia Oskouei Predicts How Adalimumab Biosimilars Can Help Biosimilar Uptake Overall
February 12th 2023Sonia T. Oskouei, PharmD, vice president of biosimilars and specialty at Sandoz, foreshadows how the US market introduction of adalimumab biosimilars could influence future biosimilar entrances and discusses why educational efforts need to be tailored to different specialties and stakeholders.
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
February 8th 2023Formycon shared positive data on its Eylea (aflibercept) biosimilar; Sandoz received a thumbs up from the European Union’s Committee for Medicinal Products for Human Use (CHMP); and Shanghai Henlius Biotech began a phase 1 study for its daratumumab biosimilar candidate.
2 Clarke Drive
Cranbury, NJ 08512